SLC6A3 and Parkinson disease: Thus, while monoamine re-uptake inhibitors may have potential as therapeutic agents in PD, the drug candidates identified so far may not possess ideal combinations of DAT activity relative to SERT or NET to enhance the actions of L-DOPA.